medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2011, Number 2

<< Back Next >>

Acta Med 2011; 9 (2)

Hyperprolactinemia. Therapeutic and diagnostic guidelines

Zárate A

Language: Spanish
References: 10
Page: 92-95
PDF size: 217.94 Kb.


ABSTRACT

Hyperprolactinemia (hyperPRL) is a frequent cause of disarrangements in reproductive area, more in women than in men. At the present PRL assays are routinely performed in clinical diagnosis of hyperPRL, and dopaminergic drugs are effective for their treatment. The use of medicaments possessed of dopamine antagonism is the most common cause of hyperPRL, but it is always necessary to discharge the presence of hypothyroidism and pituitary tumor (prolactinoma). Bromocriptine and cabergoline are the dopaminergics most common used, but ther is preference for the latter for its high effectivity and lesser side effects. Prolactinoma is well controlled with use of cabergoline and the fertility is restored rapidly.


REFERENCES

  1. Hwang P, Guyda H, Friesen HG. A radioimmunoassay for human prolactin. Proc Natl Acad Sci USA 1971; 68: 1902-1906.

  2. Melmed S et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288.

  3. Molitch ME. Pathological hyperprolactinemia. Endocrinol Met Clin North Am 1992; 21: 877-901.

  4. Zárate A, Saucedo R, Basurto L. El manejo óptimo del prolactinoma. Gaceta Med Mex 2004; 140: 567-570.

  5. del Pozo E, Broun de Re R, Varga L, Friesen HG. The inhibition of prolactin secretion in men by CB-154 (2br-alpha-ergocryptine) J Clin Endocrinol Metab 1972; 35: 768.

  6. Zárate A, Canales ES, Forsbach G. Bromocriptine: clinical experience in the induction of pregnancy in amenorrhea-galactorrhea syndrome. Obstet Gynec 1978; 52: 442-48.

  7. Zárate A, Canales ES, Alger M. The effect of pregnancy and lactation in pituitary prolactin secreting tumors. Acta Endocrinol 1979; 92: 407-410.

  8. Zárate A, Canales ES, Jacobs LS, Soria J, Daughaday WH. Restoration of ovarian function in patients with the amenorhea-galactorrhea syndrome after long term therapy with L-Dopa. Fertil Steril 1973; 24: 340-345.

  9. Schlechte JA. Prolactinoma. New Eng J Med 2003; 349: 2035-2041.

  10. Zárate A, Canales ES, Cano C, Pilonieta CJ. Follow-up of patients with prolactinoma after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol 1983; 104: 138-43.




2020     |     www.medigraphic.com